Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
ALDX Stock Chart & Stats
$5.32
-$0.07(-1.37%)
At close: 4:00 PM EST
$5.32
-$0.07(-1.37%)
Day’s Range― - ―
52-Week Range$1.14 - $7.20
Previous CloseN/A
Volume102.94K
Average Volume (3M)847.69K
Market Cap
$326.08M
Enterprise Value$276.27M
Total Cash (Recent Filing)$75.30M
Total Debt (Recent Filing)$15.54M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding60,162,773
10 Day Avg. Volume897,769
30 Day Avg. Volume847,687
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio-6.87
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.18K
Enterprise Value/Ebitda-6.73
Forecast
1Y Price Target
$9.50Price Target Upside78.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionPreclinical progress with next‑generation RASP modulator ADX‑248 supports expansion into neuroinflammatory indications such as Parkinson's disease and ALS, potentially broadening future therapeutic opportunities.
Regulatory ProgressFDA communications indicate the NDA package and pivotal trials are viewed as sufficient, with the agency prepared to propose labeling and any post‑marketing requirements if no major issues arise during review.
Strategic PartnershipAn option agreement with AbbVie provides a clear pathway to a co‑exclusive US license and potential milestone payments, supporting prospects for timely commercial access and reimbursement.
Bears Say
Clinical Trial OutcomesA completed dry eye field trial did not meet its primary symptom endpoint versus vehicle control, which raises uncertainty about the consistency of clinical benefit.
Financial PositionShifting development toward systemic RASP applications increases funding needs and could strain the current cash position, possibly necessitating external financing or partnership deals.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $326.08M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 90 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Currently, no data Available
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,162,773 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (78.57% Upside)
$9.50 (78.57% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.63%
12-Months-Change
Fundamentals
Return on Equity
-64.31%
Trailing 12-Months
Asset Growth
-33.68%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$9.50
▲(78.57% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
12.93% Insiders
8.70% Mutual Funds
0.04% Other Institutional Investors
69.18% Public Companies and
Individual Investors